6,7-Bis(2-Methoxyethoxy)-4(3H)-Quinazolinone CAS 179688-29-0 Erlotinib Hydrochloride Intermediate Purity >99.0% (HPLC)
Leading manufacturer and supplier of Erlotinib Hydrochloride Intermediate
| Erlotinib Hydrochloride | CAS 183319-69-9 |
| 3-Ethynylaniline | CAS 54060-30-9 |
| 6,7-Bis(2-Methoxyethoxy)-4(3H)-Quinazolinone | CAS 179688-29-0 |
Please contact: alvin@ruifuchem.com
| Chemical Name | 6,7-Bis(2-Methoxyethoxy)-4(3H)-Quinazolinone |
| Synonyms | 6,7-Bis(2-Methoxyethoxy)-3H-Quinazolin-4-one; 6,7-Bis(2-Methoxyethoxy)-3,4-Dihydroquinazolin-4-one; 6,7-Bis(2-Methoxyethoxy)-4-Hydroxyquinazoline; 6,7-Bis(2-Methoxyethoxy)-4-Quinazolinol; CP-380736 |
| Impurity | Erlotinib Impurity A; Erlotinib Lactam Impurity |
| CAS Number | 179688-29-0 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C14H18N2O5 |
| Molecular Weight | 294.31 |
| Melting Point | 182.0~184.0℃ |
| Density | 1.26±0.10 g/cm3 |
| WGK Germany | 3 |
| Sensitive | Air Sensitive |
| Brand | Ruifu Chemical |
| Item | Specifications | Specifications |
| Appearance | Off-White Powder | Off-White Powder |
| Purity / Analysis Method | >99.0% (HPLC) | 99.58% (HPLC) |
| Melting Point | 182.0~184.0℃ | 182.0~183.5℃ |
| Loss on Drying | <0.50% | 0.27% |
| Residue on Ignition | <0.20% | Complies |
| Heavy Metals | ≤10ppm | <10ppm |
| Related Impurities by HPLC | ||
| Individual Impurity | <0.50% | 25% |
| Total Impurities | <1.00% | 0.42% |
| Infrared Spectrum | Conforms to Structure | Complies |
| 1 H NMR Spectrum | Consistent with Structure | Complies |
| Test Standard | Enterprise Standard | Complies |
| Usage | Intermediate of Erlotinib Hydrochloride (CAS: 183319-69-9) | |
Package: Bottle, Aluminum foil bag, 25kg/Cardboard Drum, or according to customer's requirement
Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture
How to Purchase? Please contact: alvin@ruifuchem.com
15 Years Experience? We have more than 15 years of experience in the manufacture and export of a wide range of high quality pharmaceutical intermediates or fine chemicals.
Main Markets? Sell to domestic market, North America, Europe, India, Russia, Korea, Japanese, Australia, etc.
Advantages? Superior quality, affordable price, professional services and technical support, fast delivery.
Quality Assurance? Strict quality control system. Professional equipment for analysis include NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, K.F, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, etc.
Samples? Most products provide free samples for quality evaluation, shipping cost should be paid by customers.
Factory Audit? Factory audit welcome. Please make an appointment in advance.
MOQ? No MOQ. Small order is acceptable.
Delivery Time? If within stock, three days delivery guaranteed.
Transportation? By Express (FedEx, DHL), by Air, by Sea.
Documents? After sales service: COA, MOA, ROS, MSDS, etc. can be provided.
Custom Synthesis? Can provide custom synthesis services to best fit your research needs.
Payment Terms? Proforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T (Telex Transfer), PayPal, Western Union, etc.
6,7-Bis(2-Methoxyethoxy)-3H-Quinazolin-4-one (CAS: 179688-29-0) is an intermediate of Erlotinib Hydrochloride (CAS: 183319-69-9). Erlotinib Hydrochlorate is a small molecule tyrosine kinase inhibitor which acts reversibly on epidermal growth factor receptors, a hydrochloride of erlotinib, a molecular-targeted drug. The US Food and Drug Administration (FDA) has approved erlotinib (Tarceva) combined with gemcitabine as a first-line treatment for locally advanced and metastatic pancreatic cancer. It is mainly used as a second- or third-line treatment for locally advanced or metstatic non-small cell lung cancer (NSCLC) and as a treatment for pancreatic cancer. It is used as a tyrosine inhibitor for NSCLC treatment. The small molecular compound Erlotinib Hydrochlorate is a tyrosine kinase receptor inhibitor which inhibits the proliferation of tumor cells by inhibiting phosphorylation, binding to the intracellular catalytic domain of tyrosine kinase in competition with ATP, thus blocking downstream signal transduction and inhibiting activity of tumor cell ligand dependent HER-1/EGFR.
